In spite I disagree with his opinion (see for example [1]) I think it's important to keep the discussion as open as possible. The data in the article is real, and it's important to discuss it. I prefer to have a discussion about why the 20% in the submission title is a bad metric. Is it a bad metric? Why? (It looks like a result of a study that is not a RCT. It may be a good study, but I'm getting tired of reading non RCT to try to understand what they are doing and not been sure if it's a good or bad study.)
In this post I'm slightly concerned by the title. The guidelines ask to use the original title, that is "Pfizer's COVID-19 protection against infection may wane after 2 months, but it still prevents hospitalization and death for at least 6, new study finds" . It's too long.
You can be pessimist and use the first part, or optimist and use the second part. Both are opinionated reductions. The OP used a sentence somewhere in the middle of the article, that is also a possibility in case the title is too bad, but in this case it's also a very opinionated choice.